leisure time -WSS

leisure time

author：comprehensive 2025-09-30 20:34:41 - browse：1455

Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of 2023, then Pfizer CEO Albert Bourlais, unfortunately, the worst.

My annual Worst Biopharma CEO list is typically populated with blockheads and scoundrels. That’s not why Bourla is here. The reason is accountability. Strategic missteps, financial miscalculations, and scientific setbacks have plunged Pfizer into a deep crisis. Bourla is the man at the top, so the responsibility lies with him.

Pfizer shares have fallen 50% this year to their lowest level in more than a decade, erasing nearly $140 billion in market value. In 2022, the company delivered $100 billion in revenue, boosted by a widely used Covid vaccine and Covid treatment. This year, Covid product sales evaporated — and will fall further next year — leaving a vacuum Pfizer is struggling to fill with aging medicines nearing the end of their patent lives, and newer drugs and vaccines that have not performed as expected.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： In search for therapies for solid tumors, companies turn to claudin

leisure time

WSS

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Why getting cancer drugs just got harder for rural patients

FDA poised to publish guidelines for clinical trial diversity

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Liver decline slowed by off

Citing H5N1 threat, CDC urges peak flu monitoring this summer

focus

leisure time

leisure time

Novavax promises a turnaround & Lilly roils the obesity market

Change Healthcare cyberattack outage could last weeks

As demand for Covid shots wanes, Moderna seeks its next success

Eyeing GLP

Continuity nursing helped my family in our darkest PICU moments

ALS groups 'won't be played again' by the FDA, drug sponsors

Alkermes shareholders re

For longer

BioMarin wins approval for gene therapy to treat hemophilia A

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

knowledge

Eyeing GLP

Study finds gene variants tied to breast cancer risk in Black women

Liver decline slowed by off

House looks to weaken Medicare negotiation

Obesity now affects over 1 billion people worldwide, study finds

Change Healthcare cyberattack outage could last weeks

entertainment

entertainment

leisure time

Wikipedia